Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The investigators will be testing whether aminolevulinate-based (Levulan™) Photodynamic
Therapy (PDT) shows effectiveness in the treatment and prevention of cutaneous basal cell
carcinoma (BCC) in Basal Cell Nevus Syndrome (BCNS) patients. Levulan™ PDT is an FDA-approved
method widely used currently for squamous precancers of the skin. The investigators
hypothesize that PDT will provide exceptional benefit in the BCNS population because PDT is
nonmutagenic, nonscarring, and can be safely repeated many times. Additionally, the study
will investigate whether there are any differences in tumor clearance between the Blu-U®
(blue lamp) and Aktilite™(red lamp) therapies.